SuperworthCerenome CNSY
- Market cap
- $12.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $4.2M
- −21% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −189.2%
Cerenome trades at 3.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $4.2M over the last twelve months, down 21% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2M+1599% | $1.3M+770% | $1.7M+231% | $1.3M−31% | $1.5M+17% | $1.4M+8% | $1.1M−37% | $1.4M+9% | $1.4M−4% | $1.4M−3% | $1M−3% | $411K−70% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $2.5M−15% | $2.8M+31% | $2.8M−7% | $2.8M+95% | $2.9M+15% | $2.2M−22% | $1.8M−36% | $1.2M−55% | $2.4M−15% | $2.9M+35% | $2.9M+63% | $4.3M+242% |
| SG&A | $2M−10% | $2.4M−34% | $2.2M−1% | $2.2M+15% | $2.4M+20% | $3.1M+32% | $2.8M+28% | $1.7M−24% | $3.4M+44% | $4.2M+33% | $5.3M+86% | $5.2M+209% |
| −$3.3M−36% | −$3.9M−31% | −$3.3M−30% | −$3.7M+148% | −$3.8M+17% | −$3.9M+1% | −$3.5M+7% | −$1.5M−58% | −$4.5M+18% | −$5.7M+47% | −$7.1M+101% | −$9.1M+489% | |
| Interest expense | $87K−50% | $62K−61% | $34K−75% | $27K−76% | $61K−30% | $57K−8% | $548K+1512% | $0 | $0 | $0 | $17K−97% | $5K |
| Net income | −$3.2M−38% | −$3.8M−33% | −$3.3M−32% | −$2.9M+98% | −$2.9M−11% | −$3.9M+2% | −$17.4M+434% | $5.2M | −$4.4M+54% | −$5.7M+46% | −$6.9M−60% | −$9M |
| −$25.00−65% | −$21.25−66% | −$18.75−64% | −$17.75+20% | −$9.25−63% | $5.25 | −$29.86+59% | −$0.16−99% | −$1.00−89% | −$1.00 | −$1.05−97% | −$1.31+719% | |
| 129K+76% | 179.4K+100% | 172.9K+86% | 429.7K+328% | 314.2K+144% | 218.5K+22% | 582.7K+237% | 8.4M+1847% | 4.3M+1268% | 5.5M+2409% | 6.6M+1041% | 6.9M−18% |
EPS, diluted: 10 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY10 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. 12 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Cerenome's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CNSYCerenome | $12.4M | n/m | n/a | 3.0× | −21% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% |
More on Cerenome
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .